Uniquire Stock Price (NASDAQ:QURE)

Add to My Stocks
$36.41 $0.17 (0.46%) QURE stock closing price Aug 17, 2018 (Closing)
Prev Close* : $36.58
Market Cap:
$1.36B
Day Low: $35.82
52 Week Low: $7.52
Open: $36.51
Volume: -
Day High: $36.7
52 Week High: $40.99
Dividend:
0.00

Latest Stock Market News

Latest Articles

Uniquire News - From Partners

Lazy Start to Busy Week   by Zacks on Jul 24, 2018
uniQure Announces Pricing of its Public Offering   by Globe Newswire on May 02, 2018

QURE Stockcharts

View QURE PE ratio, PS ratio stocks charts and compare with peers.
QURE Chart
Note: Compare Uniquire stock price history with the index and industry peers.

Uniquire Valuation

PE ratio
(price earnings ratio)
-999.0000
PS ratio (
price to sales ratio
)
115.95
PB ratio (
price to book ratio
)
14.49

Uniquire Returns

ROE
(return on equity)
-138%

Uniquire Financial Ratios

Asset Turnover
0.07
Receivables Turnover
5.47
Debt to Equity
0.21
Dividend Yield
0%

QURE Industry Peers

Company Price Change (%)
Solid Bioscienc (SLDB)39.590.78 (2.01%)
Deciphera Pharm (DCPH)34.960.56 (1.58%)
Amgen (AMGN)197.420.98 (0.5%)
Dimension Therapeutics (DMTX)5.950 (0%)
Sangamo Therap (SGMO)15.350.1 (0.65%)
Spark Therapeutics (ONCE)61.370.64 (1.03%)
Ionis Pharma (IONS)50.840.58 (1.13%)

Top Stock Gainers

show top losers
CompanyPriceChange (%)
MiMedx (MDXG)3.890.36 (10.2%)
Organovo (ONVO)1.260.1 (8.62%)
ZIOPHARM Oncology (ZIOP)2.860.17 (6.32%)
Retrophin (RTRX)28.51.45 (5.36%)
Compugen (CGEN)3.50.15 (4.48%)
Ligand Pharma (LGND)247.988.32 (3.47%)
AVEO Pharmaceuticals (AVEO)2.330.07 (3.1%)
Top gainers from Medical-Biomed-Genetics industry
* As of Aug 18, 2018
CompanyPriceChange (%)
ELOXX PHARMACT (ELOX)11.951.83 (13.28%)
Xoma (XOMA)15.821.59 (9.13%)
IOVANCE BIOTHPT (IOVA)14.90.95 (5.99%)
Fortress Biotech (FBIO)1.910.12 (5.91%)
MannKind (MNKD)1.070.06 (5.31%)
Idera Pharma (IDRA)8.80.47 (5.07%)
Five Prime Therapeutics (FPRX)13.180.57 (4.15%)
Top losers from Medical-Biomed-Genetics industry
* As of Aug 18, 2018

Uniqure NV Stock News - Partner Headlines

Uniquire Financial Statements

income statement20172016201520142013
Net Sales or Revenues13.1M25.09M10.46M6.22M3.9M
Net Income-79.26M-73.37M-79.37M-49.21M-35.62M
Total Operating Expense84.44M97.04M85.8M51.17M32.94M
View Uniquire income statement
balance sheet20172016201520142013
Total Assets209.64M190.26M268.83M127.28M51.76M
Total Liabilities120.28M126.63M136.15M70.03M44.37M
Shareholders Equity89.35M63.63M132.67M57.25M7.39M
View Uniquire balance sheet
cash flow statement20172016201520142013
Net Increase (Decrease) in Assets Liabilities-14.67M-10.29M69.25M1.34M18.71M
Net Cash from (used by) Operating Activities-64.27M-72.18M19.07M-33.78M-5.49M
Increase (Decrease) in Prop Plant And Equipment-4.46M-15.28M-6.29M-20.95M-1.77M
View Uniquire cash flow statement

Uniquire Stock Message Board

An investor needs to spend $36.41 to buy QURE stock, as the closing Uniquire stock price is $36.41. The total market value as denoted by $1.36B for Uniquire, is the market value of the company's outstanding shares. A value investor must look at the fundamentals of a stock, and perform Uniquire valuation, even though in the short-term, sentiment and current breaking news might affect Uniquire stock price.

Demand for a stock decides its stock market price. For example, if more investors want to buy QURE stock than sell it, then Uniquire stock price goes up. Conversely, if more investors wanted to sell QURE stock than buy it, there would be greater supply than demand, and the stock price would fall. The volume number in Uniquire stock quote data shows the number of shares traded. For Ex: 138,860 Uniquire shares were traded as of last trading day, as seen from Uniquire stock chart. Dividends are usually paid by large stable companies, and typically not by those which are in their rapid growth stages. A company's continuing success is indicated by a steadily increasing dividend payout. Uniquire dividend per share was 0.00 during the last quarter. Uniquire stock price history has details about historical stock quotes, P/E ratios and price to sales ratios.